Thrombocytopenia is a possible side effect of routinely administered medical agents. Abciximab is one of the three potent intravenous glycoprotein IIb/IIIa receptor inhibitors (along with eptifibatide and tirofiban) that have shown significant positive outcomes when used in patients with intracoronary thrombus. The use of abciximab was associated with the risk of thrombocytopenia. In this case, the development of thrombocytopenia and treatment management were reported after the use of abciximab.
Abciximab glycoprotein IIb/IIIa receptor inhibitors side effect thrombocytopenia
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Case Report |
Yazarlar | |
Erken Görünüm Tarihi | 18 Mart 2022 |
Yayımlanma Tarihi | 18 Mart 2022 |
Gönderilme Tarihi | 28 Ocak 2022 |
Kabul Tarihi | 17 Mart 2022 |
Yayımlandığı Sayı | Yıl 2022 Cilt: 39 Sayı: 2 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.